Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Capricor Therapeutics (CAPR) Equity Ratio (2016 - 2025)

Capricor Therapeutics has reported Equity Ratio over the past 15 years, most recently at 0.86 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.86 for Q4 2025, up 0.68% from a year ago — trailing twelve months through Dec 2025 was 0.86 (up 0.68% YoY), and the annual figure for FY2025 was 0.86, up 0.68%.
  • Equity Ratio for Q4 2025 was 0.86 at Capricor Therapeutics, up from 0.66 in the prior quarter.
  • Over the last five years, Equity Ratio for CAPR hit a ceiling of 0.86 in Q4 2025 and a floor of 0.05 in Q3 2023.
  • Median Equity Ratio over the past 5 years was 0.52 (2023), compared with a mean of 0.52.
  • Biggest five-year swings in Equity Ratio: plummeted 116.82% in 2023 and later surged 1626.31% in 2024.
  • Capricor Therapeutics' Equity Ratio stood at 0.76 in 2021, then plummeted by 69.0% to 0.24 in 2022, then soared by 63.56% to 0.38 in 2023, then soared by 121.73% to 0.85 in 2024, then grew by 0.68% to 0.86 in 2025.
  • The last three reported values for Equity Ratio were 0.86 (Q4 2025), 0.66 (Q3 2025), and 0.79 (Q2 2025) per Business Quant data.